中國衞生集團(00673.HK)擬斥1000萬元認購一家生物科技公司10%股權
格隆匯12月22日丨中國衞生集團(00673.HK)發佈公告,於2019年12月22日,公司與一家目標公司及其100%權益的實益擁有人就公司潛在認購目標公司新股份訂立一份意向書。
目標公司為中國江蘇省一家生物科技公司,主要從事消化道腫瘤(如結腸直腸癌)早期篩查使用的體外診斷產品的研發及製造。
根據意向書,公司擬以現金認購相當於目標公司經擴大已發行股本10%的新股份,總認購價為人民幣1000萬元。各方亦有意令公司亦擁有於未來12個月內將其於目標公司的股權增加至30%的選擇權。此外,認購事項後,各方擬探索其他業務合作,涉及可能成立合營企業在中國分銷該等產品。
董事會認為,可能認購事項為公司提供了拓展參與醫療領域不同分部的機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.